Cho, Byung-Sik and Min, Gi-June and Park, Sung-Soo and Park, Silvia and Jeon, Young-Woo and Shin, Seung-Hwan and Yahng, Seung-Ah and Yoon, Jae-Ho and Lee, Sung-Eun and Eom, Ki-Seong and Kim, Yoo-Jin and Lee, Seok and Min, Chang-Ki and Cho, Seok-Goo and Kim, Dong-Wook and Wook-Lee, Jong and Kim, Myung-Shin and Kim, Yong-Goo and Kim, Hee-Je (2021) Prognostic Impacts of D816V KIT Mutation and Peri-Transplant RUNX1–RUNX1T1 MRD Monitoring on Acute Myeloid Leukemia with RUNX1–RUNX1T1. Cancers, 13 (2). p. 336. ISSN 2072-6694
![[thumbnail of cancers-13-00336-v2.pdf]](http://info.submit4journal.com/style/images/fileicons/text.png)
cancers-13-00336-v2.pdf - Published Version
Download (1MB)
Abstract
The prognostic significance of KIT mutations and optimal thresholds and time points of measurable residual disease (MRD) monitoring for acute myeloid leukemia (AML) with RUNX1-RUNX1T1 remain controversial in the setting of hematopoietic stem cell transplantation (HSCT). We retrospectively evaluated 166 high-risk patients who underwent allogeneic (Allo-HSCT, n = 112) or autologous HSCT (Auto-HSCT, n = 54). D816V KIT mutation, a subtype of exon 17 mutations, was significantly associated with post-transplant relapse and poor survival, while other types of mutations in exons 17 and 8 were not associated with post-transplant relapse. Pre- and post-transplant RUNX1–RUNX1T1 MRD assessments were useful for predicting post-transplant relapse and poor survival with a higher sensitivity at later time points. Survival analysis for each stratified group by D816V KIT mutation and pre-transplant RUNX1–RUNX1T1 MRD status demonstrated that Auto-HSCT was superior to Allo-HSCT in MRD-negative patients without D816V KIT mutation, while Allo-HSCT was superior to Auto-HSCT in MRD-negative patients with D816V KIT mutation. Very poor outcomes of pre-transplant MRD-positive patients with D816V KIT mutation suggested that this group should be treated in clinical trials. Risk stratification by both D816V KIT mutation and RUNX1–RUNX1T1 MRD status will provide a platform for decision-making or risk-adapted therapeutic approaches.
Item Type: | Article |
---|---|
Subjects: | Eurolib Press > Medical Science |
Depositing User: | Managing Editor |
Date Deposited: | 31 Dec 2022 06:31 |
Last Modified: | 01 Jul 2024 06:16 |
URI: | http://info.submit4journal.com/id/eprint/521 |